Diabetes, Vol 44, Issue 10 1147-1155, Copyright © 1995 by American Diabetes Association
Skeletal muscle mitogen-activated protein kinases and ribosomal S6 kinases. Suppression in chronic diabetic rats and reversal by vanadium
YJ Hei, X Chen, SL Pelech, J Diamond and JH McNeill
Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.
The mitogen-activated protein (MAP) kinases and ribosomal S6 protein
kinases in the skeletal muscle of insulin-resistant long-term (2 and 6
months' duration) diabetic rats were investigated to understand further the
changes in insulin intracellular signaling pathways that accompany
diabetes. The effects of insulin-mimetic vanadium compounds on the activity
of these kinases were also examined. In the insulin-resistant 2-month
diabetic rats, the basal activities of MAP kinases were relatively
unchanged, while the basal activities of S6 kinases were significantly
increased. Intravenous injection of insulin moderately activated both the
42-kDa MAP kinase (p42mapk) and a 44-kDa MAP kinase (p44erk1) in the
2-month control rats but not in the 2-month diabetic rats. Insulin
treatment markedly stimulated the activity of a novel 31-kDa S6 kinase and
the previously described 90-kDa ribosomal S6 kinase encoded by one of the
rsk genes (p90rsk) in the 2-month control rats, while the effect was
substantially reduced in the diabetic rats. In the 6-month diabetic rats,
the basal phosphotransferase activities of both MAP kinases were depressed
threefold or greater. This correlated with reductions in the amount of
immunoreactive p42mapk and p44erk1 proteins in extracts from the diabetic
rats. The basal activity of the 31-kDa S6 kinase activity was also reduced
fourfold in the 6-month diabetic rats. Treatment of the 2-month diabetic
rats with vanadyl sulfate resulted in euglycemia, prevented the increase in
the basal activity of S6 kinase, and improved the activation of S6 kinase
by insulin.(ABSTRACT TRUNCATED AT 250 WORDS)